Chlorambucil oral tablet is available as a brand-name drug. It isn’t available as a generic drug. Brand name: Leukeran. Chlorambucil comes only as a tablet you take by mouth. Chlorambucil is used to ...

Chlorambucil is a cytotoxic chemotherapy drug, prescribed for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease and lymphosarcoma. The risk or severity of adverse effects can be ...

The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic ...

Review the side-effects of Chlorambucil as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Results of the CLL14 trial, which were presented today at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois, resulted in the approval of the venetoclax ...

Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group Database A total of 100 ...

Gazyva Labeling Updated with New Efficacy Data Genentech announced that the FDA has approved the sBLA for Gazyva (obinutuzumab) in combination with chlorambucil chemotherapy in patients with ...

Chronic lymphocytic leukaemia (CLL) is a malignancy of mature B lymphocytes which occurs in older adults. A 'wait and watch' approach is taken with patients with early-stage CLL. Treatment of ...

Early and Late Therapy Response Assessment With [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial Patients (≤ 75 years ...

You have full access to this article via your institution. All subjects completed treatment, but two had significant dosing delays, one due to a mechanical ileus unrelated to therapy requiring ...

Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an ...